Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...

Sanofi added that, in partnership with Regeneron ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Sanofi noted that the HERCULES data demonstrated ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon ...

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...

One stock that might be an intriguing choice for investors right now is Sanofi SNY. This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision ...

Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple ...

About itepekimabIn partnership with Regeneron, Sanofi is exploring itepekimab, a fully human monoclonal antibody that binds to and inhibits IL33, an initiator and amplifier of broad inflammation ...

Sanofi said it is planning a phase 1/2 randomized ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...